TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy

Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with second-line Ramucirumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Graziano, Francesco, Fischer, Nicholas W., Bagaloni, Irene, Di Bartolomeo, Maria, Lonardi, Sara, Vincenzi, Bruno, Perrone, Giuseppe, Fornaro, Lorenzo, Ongaro, Elena, Aprile, Giuseppe, Bisonni, Renato, Prisciandaro, Michele, Malkin, David, Gariépy, Jean, Fassan, Matteo, Loupakis, Fotios, Sarti, Donatella, Del Prete, Michela, Catalano, Vincenzo, Alessandroni, Paolo, Magnani, Mauro, Ruzzo, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465166/
https://www.ncbi.nlm.nih.gov/pubmed/32722340
http://dx.doi.org/10.3390/cancers12082049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465166/
https://www.ncbi.nlm.nih.gov/pubmed/32722340
http://dx.doi.org/10.3390/cancers12082049

Ejemplares similares